Dabigatran Etexilate Mesylate

达比加群酯甲磺酸盐

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameDabigatran Etexilate Mesylate
Drug Alias Namedabigatranum etexilatum甲磺酸达比加群酯达比加群乙酯Dabigatran etexilate mesilateDabigatran Etexilate Methanesulfonate +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProthrombin inhibitors
TargetsProthrombin
Therapy Area/IndicationsIschemic StrokeCognitive DysfunctionScleroderma, Systemic +[21] 
Global Approved IndicationsVenous ThrombosisVenous ThromboembolismEmbolism +[5] 
Approved Indications in ChinaEmbolismStroke
Original Approved Country/TerritoryEU
Original Approved Date2008/03/17
Country/TerritoryCzechiaBelgiumBulgaria +[49] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgBoehringer Ingelheim Pharmaceuticals IncBoehringer Ingelheim International Gmbh
Inactive CompaniesUniversity Of AlbertaUniversity Of Rhode IslandKorea University +[5] 
Active IndicationsVenous ThrombosisVenous ThromboembolismEmbolism +[5] 
Inactive IndicationsIschemic StrokeCognitive DysfunctionScleroderma, Systemic +[16] 

Other Information

ATC CodeB01AE07
Related LinksWikipediaDrugBankKEGG